Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antineoplastic agent
nitrogen mustard |
| gptkbp:approvalYear |
2008
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01AA09
|
| gptkbp:brand |
gptkb:Bendeka
gptkb:Treanda |
| gptkbp:CASNumber |
16506-27-7
|
| gptkbp:chemicalFormula |
C16H21Cl2N3O2
|
| gptkbp:contraindication |
hypersensitivity
|
| gptkbp:developedBy |
gptkb:Germany
|
| gptkbp:discoveredIn |
1963
|
| gptkbp:eliminationHalfLife |
30 minutes
|
| https://www.w3.org/2000/01/rdf-schema#label |
bendamustine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antineoplastic agent
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
358.27 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea fatigue rash infusion reactions myelosuppression |
| gptkbp:usedFor |
leukemia
multiple myeloma chronic lymphocytic leukemia |
| gptkbp:bfsParent |
gptkb:Polivy
|
| gptkbp:bfsLayer |
7
|